Company News: Page (1) of 1 - 12/18/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032

(December 18, 2017)

RALEIGH, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance of BDSI’s patent application, that once formally granted, will be Orange Book listed and will extend the exclusivity of BELBUCA® (buprenorphine) buccal film from July 2027 to December 2032.  The patent (U.S. Patent Application Serial No. 13/724,959) covers the method of using BioErodible MucoAdhesive (BEMA®) for the treatment of chronic pain. 

“We are pleased the Patent Office has allowed this important patent covering BELBUCA,” said Dr. Mark A. Sirgo, Vice Chairman, President and CEO of BDSI.  “Beyond the significant growth we have seen with BELBUCA in 2017, this patent provides a substantial length of time for BELBUCA to continue to grow and become well established in the market.”

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence.  BDSI's headquarters is in Raleigh, North Carolina.  

For more information, please visit or follow us: 

Internet: www.bdsi.com 
Facebook: Facebook.com/BioDeliverySI
Twitter:  @BioDeliverySI
   

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences.   For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, any implied benefits of the patent described herein) may differ significantly from those set forth or implied in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA®, ONSOLIS®, BUNAVAIL® and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc.  All other trademarks and tradenames are owned by their respective owners.

© 2017 BioDelivery Sciences International, Inc.  All rights reserved.

Contacts


Investors:
Al Medwar
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc. 
919-582-9050
[email protected]

Monique Kosse
Managing Director 
LifeSci Advisors
212-915-3820
[email protected]


Page: 1


Related Keywords:

[ServletException in:/common/ads/links.jsp] Unable to load class for JSP'

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved